Successful Rapid Desensitization of Two Teenagers with Rituximab HypersensitivityCorrespondence Address :
Department of Paediatric Allergy and Immunology, Erciyes University, Kayseri, Medical Faculty, Turkey.
Rituximab is one of the monoclonal antibodies that is used in the management of malignancies and auto-inflammatory disorders. Rituximab causes Hypersensitivity Reactions (HSRs) during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. Although HSRs and desensitization protocols to mAbs have been well described in adults, the experience in the paediatric population is very limited. To best of authors knowledge, this is the first case series describing a novel, rapid desensitization protocol against rituximab hypersensitivity in two teenagers with high-grade B cell non-Hodgkin’s lymphoma and steroid-resistant minimal change disease who developed hypersensitivity to rituximab. Here, authors present case reports of two patients who were desensitized successfully by using novel rapid desensitization protocol for rituximab.
Anaphylaxis, Minimal change disease rituximab, Non-hodgkin lymphoma
Murat Cansever, Alper Ozcan, Ismail Dursun, Ekrem Unal, Fulya Tahan. SUCCESSFUL RAPID DESENSITIZATION OF TWO TEENAGERS WITH RITUXIMAB HYPERSENSITIVITY. Journal of Clinical and Diagnostic Research [serial online] 2019 May [cited: 2019 May 19 ]; 13:SD01-SD03. Available from
Date of Submission: Jul 31, 2018
Date of Peer Review: Sep 12, 2018
Date of Acceptance: Jan 21, 2019
Date of Publishing: May 01, 2019
FINANCIAL OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)